Biocept (BIOC) Stock Price Up 6.3%

Biocept Inc (NASDAQ:BIOC) shares rose 6.3% during mid-day trading on Friday . The stock traded as high as $0.36 and last traded at $0.34. Approximately 5,239,687 shares changed hands during mid-day trading, an increase of 98% from the average daily volume of 2,640,951 shares. The stock had previously closed at $0.32.

Separately, Zacks Investment Research lowered shares of Biocept from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.41 and a quick ratio of 1.27. The firm has a market cap of $21.84, a P/E ratio of -0.39 and a beta of 1.74.

An institutional investor recently bought a new position in Biocept stock. Sabby Management LLC acquired a new position in shares of Biocept Inc (NASDAQ:BIOC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 962,265 shares of the medical research company’s stock, valued at approximately $668,000. Sabby Management LLC owned about 1.51% of Biocept at the end of the most recent quarter. 9.29% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3299581/biocept-bioc-stock-price-up-6-3.html.

Biocept Company Profile

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group
Show  Reaches Market Cap of $0.00
Show Reaches Market Cap of $0.00
PayCoin  Price Tops $0.0344 on Major Exchanges
PayCoin Price Tops $0.0344 on Major Exchanges
UGAIN Price Reaches $0.0031
UGAIN Price Reaches $0.0031
Reviewing Sally Beauty  and Kirkland’s Home
Reviewing Sally Beauty and Kirkland’s Home
Comparing CGG  and Paramount Resources
Comparing CGG and Paramount Resources


© 2006-2018 Ticker Report. Google+.